Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | IDE | P14735 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29849887 | 1.00 | NOS1 (0.42) | NOS1NOS2L3MBTL1CYP3A4ALDH1A1 | |
| SCHEMBL28402473 | 0.83 | ALDH1A1 (0.40) | L3MBTL1CYP3A4ALDH1A1CYP1A2TSHR | |
| SCHEMBL14330650 | 0.80 | CYP1A2 (0.46) | L3MBTL1CYP3A4ALDH1A1CYP1A2MAPT | |
| SCHEMBL14332032 | 0.78 | HTT (0.46) | L3MBTL1CYP3A4ALDH1A1CYP1A2MAPT | |
| SCHEMBL1171499 | 0.78 | POLB (0.47) | L3MBTL1CYP1A2MAPTTSHRGAA | |
| SCHEMBL24355439 | 0.77 | GAA (0.49) | NOS1NOS2L3MBTL1CYP3A4ALDH1A1 | |
| SCHEMBL20271838 | 0.76 | L3MBTL1 (0.41) | L3MBTL1CYP3A4ALDH1A1CYP1A2MAPT | |
| SCHEMBL14330634 | 0.76 | TSHR (0.41) | L3MBTL1CYP3A4CYP1A2MAPTABCB11 | |
| SCHEMBL12302777 | 0.75 | SYK (0.55) | L3MBTL1MAPTLMNA | |
| SCHEMBL17420686 | 0.74 | KDM4E (0.46) | L3MBTL1CYP3A4ALDH1A1CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022173849-A1 | (HETERO)ARYLAMINO-CYCLOHEXYL-SULFONYL DERIVATIVES AS CCR6 INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2022-08-18 | — | — | WO | disclosed |
| EP-2721021-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS NC INC (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-2721020-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS NC INC (US) | 2019-01-23 | — | — | EP | disclosed |
| US-9556143-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9221791-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150099750-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-04-09 | — | — | US | disclosed |
| US-8901121-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140350003-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2014-11-27 | — | — | US | disclosed |
| US-8809378-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2721021-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2721020-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20130005719-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2012177603-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177608-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | NOS1 1329/4885NOS2 1150/4885L3MBTL1 1568/4885 |
| US-20150099750-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | NOS1 1329/4885NOS2 1150/4885L3MBTL1 1568/4885 |
| US-20140350003-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | NOS1 1329/4885NOS2 1150/4885L3MBTL1 1568/4885 |
| US-20130005719-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | NOS1 1329/4885NOS2 1150/4885L3MBTL1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.